Schmitt J, Stoller E, Wozel G
Klinik und Poliklinik für Dermatologie, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden.
Hautarzt. 2005 Apr;56(4):360-2. doi: 10.1007/s00105-004-0831-3.
Alefacept, a recombinant protein produced by fusion of human LFA(3 )and IgG(1), was the first biologic specially designed and approved for the treatment of psoriasis. Results of clinical trials reveal both an efficacy comparable to established systemic therapies and a high drug safety. A 62-year old male patient with psoriasis and incomplete response to several standard therapies was treated with alefacept (baseline PASI 23.1). After three courses of 15 mg alefacept i.m. weekly for 12 weeks, each followed by a 12 week post-dosing observation period, the PASI regressed to 2.0. Adverse drug reactions were not observed.
阿法赛特是一种通过将人淋巴细胞功能相关抗原-3（LFA-3）与免疫球蛋白G1（IgG1）融合产生的重组蛋白，是首个专门设计并获批用于治疗银屑病的生物制剂。临床试验结果显示其疗效与已有的全身治疗相当，且药物安全性高。一名62岁男性银屑病患者对多种标准治疗反应不完全，接受了阿法赛特治疗（基线银屑病面积和严重程度指数PASI为23.1）。每周肌肉注射15毫克阿法赛特，共12周，进行三个疗程，每个疗程后有12周的给药后观察期，之后PASI降至2.0。未观察到药物不良反应。
